Form 4: CVS Health CFO Brian Newman Receives Significant Equity Awards

CVS Health's Executive Vice President and Chief Financial Officer, Brian Newman, was granted 21,861 restricted stock units and 94,786 stock options on May 31, 2025, as part of the company's incentive compensation plan.

Summary

• Brian Newman, Executive Vice President and Chief Financial Officer of CVS Health Corp. (CVS), acquired equity securities on May 31, 2025.
• Newman was granted 21,861 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $64.04 per share.
• These RSUs were awarded pursuant to the Issuer's 2017 Incentive Compensation Plan, with restrictions lapsing in four equal installments commencing May 31, 2026.
• Additionally, Newman acquired 94,786 stock options with an exercise price of $64.04 per share.
• These stock options become exercisable in four equal annual installments, commencing May 31, 2026, and have an expiration date of May 31, 2035.
• Following these transactions, Newman beneficially owns 21,861 shares of Common Stock (RSUs) and 94,786 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a routine grant of equity compensation to a key executive, which is generally viewed as a positive for aligning management incentives with shareholder interests, but it does not contain new operational or financial performance data.

Positives

• The granting of equity awards to a key executive like the CFO aligns management's interests with shareholders, incentivizing long-term performance.
• The awards are part of an established incentive compensation plan (2017 Incentive Compensation Plan), indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule for RSUs and exercisability for stock options extends into the future (commencing May 31, 2026), indicating a long-term incentive structure for the CFO aimed at aligning his interests with the company's sustained performance.

Industry Context

Executive equity compensation, such as the granting of Restricted Stock Units and stock options, is a standard practice across various industries, including healthcare and retail pharmacy. This approach is widely adopted to align executive incentives with company performance and long-term shareholder value, reflecting common corporate governance practices.

Comparison to Industry Standards

• The granting of performance-based equity awards (RSUs and stock options) to senior executives like the CFO is a common practice in large publicly traded companies, including peers in the healthcare and pharmacy benefit management sectors such as UnitedHealth Group, Cigna, and Humana.
• The specific value and structure of these awards would typically be benchmarked against compensation practices for similar roles in companies of comparable size and complexity within the industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term shareholder value through equity ownership.

Next Steps

• Future vesting of RSUs and exercisability of stock options will occur on their respective schedules, commencing May 31, 2026.

Key Dates

Keywords

CVS Health, Brian Newman, Form 4, SEC filing, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Equity Awards, CFO